Multicenter double-blind randomized phase II: FOLFOX plus ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA)

被引：20
|
作者：
Enzinger, Peter C.
McCleary, Nadine Jackson
Zheng, Hui
Abrams, Thomas Adam
Yurgelun, Matthew B.
Azzoli, Christopher G.
Cleary, James M.
Rubinson, Douglas Adam
Brooks, Gabriel
Chan, Jennifer A.
Goyal, Lipika
Meyerhardt, Jeffrey A.
Ng, Kimmie
Schrag, Deborah
Savarese, Diane M. F.
Graham, Christopher
Carey, Margaret M.
Fuchs, Charles S.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[4] MGH Canc Ctr, Brookline, MA USA
[5] Div Hematol Oncol, Waltham, MA USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页数：1
相关论文
共 50 条
  • [21] DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED PHASE III TRIAL OF AFLIBERCEPT (A) PLUS GEMCITABINE (G) VERSUS PLACEBO (P) PLUS GEMCITABINE (G) IN PATIENTS WITH METASTATIC PANCREATIC CANCER: FINAL RESULTS
    Riess, H.
    Manges, R.
    Karasek, P.
    Humblet, Y.
    Barono, C.
    Santoro, A.
    Wojcik-Tomaszewska, J.
    Assadourian, S.
    Hatteville, L.
    Vincent, G.
    Philip, P.
    Rougier, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [22] Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST
    Demetri, GD
    van Oosterom, AT
    Blackstein, M
    Garrett, C
    Shah, M
    Heinrich, M
    McArthur, G
    Judson, I
    Baum, CM
    Casali, PG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 308S - 308S
  • [23] A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)
    Kuboki, Y.
    Yoshino, T.
    Yamazaki, K.
    Nishina, T.
    Komatsu, Y.
    Baba, H.
    Tsuji, A.
    Yamaguchi, K.
    Muro, K.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S392 - S392
  • [24] A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data.
    Moehler, M. H.
    Schimanski, C. C.
    Kanzler, S.
    Woerns, M. A.
    Denzer, U.
    Kolligs, F. T.
    Ebert, M. P.
    Distelrath, A.
    Geissler, M.
    Zeuzem, S.
    Lammert, F.
    Lohse, A. W.
    Dollinger, M. M.
    Lindig, U.
    Duerr, E. M.
    Lubomierski, N.
    Zimmermann, S.
    Kabisch, M.
    Schadmann-Fischer, S.
    Galle, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
    Davis, Lara E.
    Bolejack, Vanessa
    Ryan, Christopher W.
    Ganjoo, Kristen N.
    Loggers, Elizabeth T.
    Chawla, Sant
    Agulnik, Mark
    Livingston, Michael B.
    Reed, Damon
    Keedy, Vicky
    Rushing, Daniel
    Okuno, Scott
    Reinke, Denise K.
    Riedel, Richard F.
    Attia, Steven
    Mascarenhas, Leo
    Maki, Robert G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (16) : 1424 - +
  • [26] Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study
    Bang, Yung-Jue
    Im, Seock-Ah
    Lee, Keun-Wook
    Cho, Jae Yong
    Song, Eun-Kee
    Lee, Kyung Hee
    Kim, Yeul Hong
    Park, Joon Oh
    Chun, Hoo Geun
    Zang, Dae Young
    Fielding, Anitra
    Rowbottom, Jacqui
    Kim, Woo Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer
    Zhao, Xiao-Yin
    Liu, Xin
    Li, Wen-Hua
    Qiu, Li-Xin
    Huang, Ming-Zhu
    Wang, Chen-Chen
    Chen, Zhi-Yu
    Zhang, Wen
    Feng, Wan-Jing
    Guo, Wei-Jian
    Zhu, Xiaodong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).
    Bendel, Johanna C.
    Sauri, Tamara
    Cubillo, Antonio
    Lopez-Lopez, Carlos
    Alfonso, Pilar Garcia
    Hussein, Maen A.
    Limon, M. Luisa
    Cervantes, Andres
    Montagut, Clara
    Santos, Cristina
    Bessudo, Alberto
    Modiano, Manuel R.
    Moons, Veerle
    Andel, Johannes
    Jaafar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study
    Rini, B. I.
    Szczylik, C.
    Tannir, N. M.
    Koralewski, P.
    Tomczak, P.
    Deptala, A.
    Kracht, K.
    Sun, Y.
    Puhlmann, M.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [30] Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas
    Saif, Muhammad Wasif
    Oettle, H.
    Vervenne, W. L.
    Thomas, J. P.
    Spitzer, G.
    Visseren-Grul, C.
    Enas, N.
    Richards, D. A.
    CANCER JOURNAL, 2009, 15 (04): : 339 - 343
12345